Evofem Biosciences, Inc.
Other OTCTotal Valuation
Evofem Biosciences, Inc. carries a market capitalization of 1.06M, placing it among publicly traded companies globally. Its enterprise value stands at 52.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.06M |
| Enterprise Value | 52.05M |
Share Statistics
Evofem Biosciences, Inc. currently has 132.53M shares outstanding.
| Shares Outstanding | 132.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Evofem Biosciences, Inc. trades at a trailing price-to-earnings ratio of 3.02. The price-to-sales ratio is 0.05, and the price-to-book ratio stands at 0.00.
| PE Ratio | 3.02 |
| PS Ratio | 0.05 |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | -4.43 |
| P/OCF Ratio | -4.31 |
Enterprise Valuation
The EV/Sales ratio of 2.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.91 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.57 |
| EV / EBITDA | 26.42 |
| EV / EBIT | 37.91 |
| EV / FCF | N/A |
Financial Position
Evofem Biosciences, Inc. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.08 |
| Quick Ratio | 0.03 |
| Debt / Equity | -67.57 |
| Debt / EBITDA | -17.57 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -59.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | 1,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Evofem Biosciences, Inc.'s stock has declined approximately -13.60691% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -13.60691% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Evofem Biosciences, Inc. generated 20.24M in revenue and converted that into -6.03M in net income, yielding earnings per share of -0.05. EBITDA reached -2.99M, while operating income came in at -3.46M.
| Revenue | 20.24M |
| Gross Profit | 15.58M |
| Operating Income | -3.46M |
| Pretax Income | -6.03M |
| Net Income | -6.03M |
| EBITDA | -2.99M |
| EBIT | -3.46M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
Evofem Biosciences, Inc. holds 1.49M in cash and equivalents against 52.46M in total debt, resulting in a net debt position of 50.82M. Total book value stands at -902.86M, with working capital of -72.70M providing operational flexibility.
| Cash & Cash Equivalents | 1.49M |
| Total Debt | 52.46M |
| Net Debt | 50.82M |
| Equity (Book Value) | -902.86M |
| Book Value Per Share | -7.35 |
| Working Capital | -72.70M |
Cash Flow
Evofem Biosciences, Inc. produced -251,000.00 in operating cash flow over the past twelve months. After subtracting -7,000.00 in capital expenditures, free cash flow totaled -258,000.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -251,000.00 |
| Capital Expenditures | -7,000.00 |
| Free Cash Flow | -258,000.00 |
| FCF Per Share | 0.00 |
Margins
Evofem Biosciences, Inc. operates with a gross margin of 76.96, reflecting its pricing power and cost economics. The operating margin of -17.08 and net profit margin of -29.80 provide insight into operational efficiency.
| Gross Margin | 76.96 |
| Operating Margin | -17.08 |
| Pretax Margin | -29.79 |
| Profit Margin | -29.80 |
| EBITDA Margin | -14.76 |
Dividends & Yields
The company's payout ratio of 2.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 2.17 |
| Shareholder Yield | -141.36 |
| FCF Yield | -22.57 |
Stock Splits
Evofem Biosciences, Inc.'s most recent stock split took place on May 18, 2023 with a 125:1 split ratio.
| Last Split Date | 5/18/2023 |
| Split Ratio | 125:1 |
Scores
Evofem Biosciences, Inc. posts an Altman Z-Score of -201.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -201.44 |